Contrasting BioHarvest Sciences (NASDAQ:BHST) & Haleon (NYSE:HLN)

Haleon (NYSE:HLN) and BioHarvest Sciences (NASDAQ:BHST) are both consumer staples companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

6.7% of Haleon shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Haleon has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Comparatively, BioHarvest Sciences has a beta of 0.93, indicating that its stock price is 7% less volatile than the S&P 500.

Earnings and Valuation

This table compares Haleon and BioHarvest Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Haleon	$14.54 billion	2.76	$2.20 billion	$0.39	23.40
BioHarvest Sciences	$34.51 million	0.90	-$11.14 million	($0.52)	-3.06

Haleon has higher revenue and earnings than BioHarvest Sciences. BioHarvest Sciences is trading at a lower price-to-earnings ratio than Haleon, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Haleon and BioHarvest Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Haleon	N/A	N/A	N/A
BioHarvest Sciences	-31.21%	-58.30%	-25.60%

Analyst Ratings

This is a summary of current recommendations for Haleon and BioHarvest Sciences, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Haleon	1	5	2	2	2.50
BioHarvest Sciences	1	0	2	0	2.33

Haleon currently has a consensus target price of $4.90, indicating a potential downside of 46.30%. BioHarvest Sciences has a consensus target price of $6.50, indicating a potential upside of 308.81%. Given BioHarvest Sciences’ higher possible upside, analysts clearly believe BioHarvest Sciences is more favorable than Haleon.

Summary

Haleon beats BioHarvest Sciences on 11 of the 13 factors compared between the two stocks.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

About BioHarvest Sciences

BioHarvest Sciences Inc. is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications. BioHarvest Sciences Inc. is based in Vancouver, Canada.